Fior-Markets-Logo.jpg
Global Alzheimer’s Therapeutics Market is Expected to Reach USD 8.19 Billion By 2026 : Fior Markets
July 09, 2019 07:57 ET | Fior Markets
New Jersey, NJ, July 09, 2019 (GLOBE NEWSWIRE) -- Fior Markets launched a study titled "Alzheimer’s Therapeutics Market by Drug Type (Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor...
RND logo.PNG
Alzheimer’s Therapeutics Market to Reach USD 12.43 Billion By 2026 | Reports And Data
May 02, 2019 12:00 ET | Reports And Data
Rising incidence of investment in biomarkers for drug development is the major factor influencing market growth. Market Size – USD 18.23 billion in 2018, Market Growth - CAGR of 4.6%, Market Trends...
Otonomy, Inc. Logo
Otonomy to Report Second Quarter 2018 Financial Results and Provide Corporate Update
August 01, 2018 16:05 ET | Otonomy, Inc.
SAN DIEGO, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced it will...
Otonomy, Inc. Logo
Otonomy Successfully Completes Open-Label Clinical Trial for OTIPRIO® in Patients with History of Otitis Media Requiring Tympanostomy Tubes
September 15, 2016 07:30 ET | Otonomy, Inc.
SAN DIEGO, Sept. 15, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy, Inc. Logo
Otonomy Successfully Completes One-Year, Multiple-Dose Clinical Safety Trial for OTO-104 in Ménière’s Disease Patients
August 01, 2016 07:30 ET | Otonomy, Inc.
SAN DIEGO, Aug. 01, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy, Inc. Logo
Otonomy to Report Second Quarter 2016 Financial Results and Provide Corporate Update
July 28, 2016 16:30 ET | Otonomy, Inc.
SAN DIEGO, July 28, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy, Inc. Logo
Otonomy Reports First Quarter 2016 Financial Results and Provides Corporate Update
May 09, 2016 16:15 ET | Otonomy, Inc.
SAN DIEGO, May 09, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy, Inc. Logo
Otonomy to Present at the Bank of America Merrill Lynch Healthcare Conference
May 05, 2016 07:30 ET | Otonomy, Inc.
SAN DIEGO, May 05, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy, Inc. Logo
Otonomy Initiates Patient Enrollment in Second Phase 3 Clinical Trial of OTO-104 in Ménière’s Disease
March 23, 2016 07:30 ET | Otonomy, Inc.
SAN DIEGO, March 23, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy, Inc. Logo
Otonomy Announces Publication of OTIPRIO™ Phase 3 Clinical Trial Results in JAMA Otolaryngology
March 18, 2016 07:30 ET | Otonomy, Inc.
SAN DIEGO, March 18, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...